Iovance Biotherapeutics (IOVA) 8-K Changes in Registrant's Certifying Accountant

Exhibit 16.1

April 7, 2016

Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549-7561

Dear Sirs/Madams:

We have read Item 4.01(a) of Lion Biotechnologies Inc.’s Form 8-K dated April 7, 2016, and we agree with the statements made therein. We have no basis on which to agree or disagree with the statements made in Item 4.01(b).

Yours truly,

/s/ Weinberg & Company, P.A.

Los Angeles, California